8 completed, 6 unknown, 2 not yet recruiting, 2 terminated. 20 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 8, Unknown 6, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Febrile Neutropenia: new trials by email Literature Review of Febrile Neutropenia trials Research Report on Febrile Neutropenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. amoxicillin-clavulanate, Amoxicillin-clavulanate ciprofloxacin - C15.378 | Phase 3 | Not yet recruiting | Versailles Hospital | 1526 | 2026-03-01 | 2026-03-19 |
| Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.) - Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female | Phase 3 | Active not recruiting | Kexing Biopharm Co., Ltd. | 250 | 2025-01-09 | 2025-11-25 |
| Early Neutropenic Fever De-escalation of Antibiotics Study Cessation of antibiotics - Hematologic Malignancy, Febrile Neutropenia | Phase 3 | Not yet recruiting | Brigham and Women's Hospital | 260 | 2024-03-01 | 2024-02-26 |
| Lapelga vs Gastrofil Grastofil®, Lapelga - Multiple Myeloma, Lymphoma | Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 74 | 2023-11-01 | 2023-11-03 |
| A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia Fosfomycin Calcium - Febrile Neutropenia | Phase 3 | Unknown | Fundación para la Investigación Biosanitaria del Principado de Asturias | 156 | 2022-03-14 | 2023-09-14 |
| Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial. Placebo, Amoxicillin Clavulanate, Ciprofloxacin - Febrile Neutropenia | Phase 3 | Withdrawn | Poitiers University Hospital | 2022-03-01 | 2022-03-31 | |
| Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF - Non-Myeloid Malignancy | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 398 | 2020-10-16 | 2022-02-09 |
| Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor - Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced | Phase 3 | Unknown | Lei Li | 200 | 2019-10-01 | 2019-10-08 |
| Long-acting G-CSF for Febrile Neutropenia long-acting granulocyte colony stimulating factor, Short-term granulocyte colony stimulating factor - Epithelial Ovarian Cancer, Colony Stimulating Factors | Phase 3 | Unknown | Lei Li | 556 | 2018-11-10 | 2018-11-14 |
| Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study stoppage of antibiotics, amoxycillin/clavulanic acid, levofloxacin - Neutropenia, Febrile, Pediatric Cancer | Phase 3 | Terminated | All India Institute of Medical Sciences | 142 | 2017-01-01 | 2019-02-01 |
| Efficacy and Safety Study With MYL-1401H and Neulasta MYL-1401H, Neulasta - Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia | Phase 3 | Completed | Mylan Inc. | 193 | 2015-03-01 | 2022-02-14 |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML G-CSF - Leukemia, Myeloid, Acute | Phase 2 / Phase 3 | Unknown | Seoul St. Mary's Hospital | 56 | 2015-03-01 | 2015-04-28 |
| Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Empegfilrastim 6 mg, Filgrastim, Placebo №1 - Chemotherapy-induced Neutropenia | Phase 3 | Completed | Biocad | 135 | 2013-09-01 | 2016-10-24 |
| A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, placebo and rhG-CSF 5ug/kg/d - NSCLC, Neutropenia | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 150 | 2012-04-01 | 2012-11-06 |
| A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy Drug: Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, rhG-CSF 5ug/kg/day - Breast Cancer, Neutropenia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 330 | 2012-03-01 | 2013-01-08 |
| Daptomycin Versus Placebo in Patients With Neutropenia and Fever Daptomycin, Saline Placebo - Febrile Neutropenia | Phase 3 | Terminated | University of Rochester | 36 | 2011-04-01 | 2014-04-10 |
| PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study Pegfilgrastim, Placebo, Bevacizumab - Cancer, Colon Cancer | Phase 3 | Completed | Amgen | 847 | 2009-11-03 | 2017-12-29 |
| Various G-CSF Regimens to Prevent Infection During Chemotherapy pegfilgrastim - Breast Cancer, Chemotherapy | Phase 3 | Completed | Academisch Ziekenhuis Maastricht | 172 | 2008-01-01 | 2019-11-06 |
| Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases ciprofloxacin, cefepime - Febrile Neutropenia | Phase 3 | Completed | Center for Supporting Hematology-Oncology Trials | 51 | 2005-04-01 | 2018-06-26 |
| Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection linezolid, vancomycin - Febrile Neutropenia | Phase 3 | Completed | Pfizer | 120 | 2001-11-01 | 2009-12-01 |
Neutropenia (6) · Breast Neoplasms (4) · Chemotherapy-Induced Febrile Neutropenia (3) · Carcinoma, Ovarian Epithelial (2) · Neoplasms (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Fever (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Multiple Myeloma (1) · Patient Participation (1)
Agranulocytosis (20) · Cytopenia (20) · Hemic and Lymphatic Diseases (20) · Leukocyte Disorders (20) · Leukopenia (20) · Hematologic Diseases (19) · Neutropenia (14) · Neoplasms (9) · Neoplasms by Site (8) · Breast Diseases (4) · Neoplasms by Histologic Type (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Adnexal Diseases (2)
Amoxicillin-Potassium Clavulanate Combination (3) · pegfilgrastim (3) · Ciprofloxacin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Bevacizumab (1) · Cefepime (1) · Daptomycin (1) · Levofloxacin (1) · Linezolid (1) · Long-Term Synaptic Depression (1) · MYL-1401H (1) · TKN732 (1) · Vancomycin (1) · pegylated granulocyte colony-stimulating factor (1)
Jiangsu HengRui Medicine Co., Ltd. (2) · Lei Li (2) · Academisch Ziekenhuis Maastricht (1) · All India Institute of Medical Sciences (1) · Amgen (1) · Biocad (1) · Brigham and Women's Hospital (1) · Center for Supporting Hematology-Oncology Trials (1) · Fundación para la Investigación Biosanitaria del Principado de Asturias (1) · Kexing Biopharm Co., Ltd. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mylan Inc. (1) · Pfizer (1) · Poitiers University Hospital (1) · Seoul St. Mary's Hospital (1)
China (6) · United States (3) · Bulgaria (2) · France (2) · Hungary (2) · Mexico (2) · Poland (2) · Russia (2) · Ukraine (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1)
Lei Li, M.D. (2) · Alexander Pecheny, PhD (1) · Andrei Horinko, MD (1) · Andrei Rusin, MD,PhD (1) · Andrei Sinykov, PhD (1) · Bogdan Kotiv, MD, PhD (1) · Byakhov Michael, MD, PhD (1) · Caicun Zhou (1) · Daniil Stroyakovsky (1) · Dmitriy Udovica, MD (1) · Guzel Mukhametshina, MD (1) · Igor Lifirenko, MD (1) · Igor Pimenov, PhD (1) · Igor Sedakov, MD, PhD (1) · Irina Davydenko, PhD (1)
PMID 23317527, PMID 24166522, PMID 30824956, PMID 31467066, PMID 37891616, PMID 40098083, PMID 42164340
2014 (1), 2025 (1)